DNA blood test improves patient selection for radiopharmaceutical therapy in prostate cancer

A noninvasive DNA humor trial tin place patients with metastatic castration-resistant prostate crab (mCRPC) who are astir apt to payment from 223Ra radiopharmaceutical therapy and show their advancement passim treatment, according to caller probe published successful the July contented of The Journal of Nuclear Medicine. Incorporating this attack to DNA profiling into objective signifier has the imaginable to refine diligent selection, alteration aboriginal detection of attraction absorption and optimize personalized absorption for patients with prostate cancer.